Multiple Breast Masses Research Articles

Imaging Enigma in Mastitis: A Comprehensive study of Multifaceted Causes, Clinical and Radiological Presentations

Mastitis is an inflammatory condition of the breast which represents an array of underlying etiologies encompassing both infectious and non-infectious causes. Exacerbating factors include endemic infections, lack of awareness and suboptimal breastfeeding practices. Neglected cases lead to prolonged morbidity, recurrent episodes, and complications such as abscess or sinus formation, resulting in permanent breast disfigurement. Its overlapping clinical presentation with breast cancer necessitates an integrated multidisciplinary approach for diagnosis and treatment. The primary aim was to investigate demographic, radiological, and histopathological characteristics of mastitis. Objectives included correlating radiological and histopathological findings, classifying mastitis by etiology, identifying the clinical and imaging patterns across diverse clinical settings to enhance the understanding of mastitis. This is a retrospective observational study, analysing the clinical, radiological, and histopathological data from 65 patients with mastitis between February 2023 and February 2024. The study included 65 patients, aged 18 to 65 years, with breast pain as the most prevalent clinical presentation. Cases were classified as infectious (47.6%) and non-infectious (52%). Acute puerperal mastitis (26.15%) and granulomatous mastitis (30%) were the most common subtypes. The commonest mammographic finding was focal asymmetry. On ultrasound, infectious mastitis showed oedema with other inflammatory changes, including diffuse skin thickening and collections; while non-infectious mastitis typically presented as solitary or multiple breast masses (p < 0.001). Surprisingly, idiopathic granulomatous mastitis constituted the largest percentage amongst various histopathological causes of mastitis in our study. An integrated multidisciplinary approach with understanding of the pathogenesis is imperative for prompt diagnosis and optimizing treatment strategies, thereby improving patient outcome. Radiological imaging is critical for diagnosis, evaluating disease extent, conducting guided interventions, and monitoring treatment response.

Clinical characteristics and survival of second primary breast carcinoma with extramammary malignancies.

To investigate the characteristics, diagnosis, survival and prognosis of second primary breast carcinoma (SPBC). Records of 123 patients with SPBC in Tianjin Medical University Cancer Institute & Hospital between December 2002 and December 2020 were retrospectively reviewed. Clinical characteristics, imaging features and survival were analyzed and comparisons between SPBC and breast metastases (BM) were made. Of 67156 newly diagnosed breast cancer patients, 123 patients (0.18%) suffered previous extramammary primary malignancies. Of the 123 patients with SPBC, approximately 98.37%(121/123)were female. The median age was 55 years old (27-87). The average diameter of breast mass was 2.7 cm (0.5-10.7). Approximately 77.24% (95/123) of the patients presented with symptoms. The most common types of extramammary primary malignancies were thyroid, gynecological cancers, lung, and colorectal. Patients with the first primary malignant tumor of lung cancer were more likely to develop synchronous SPBC, and those with the first primary malignant tumor of ovarian cancer were more likely to develop metachronous SPBC. When comparing with BM, patients with SPBC were more often older (≥45 years old), at earlier stages (I/II), more microcalcification and less multiple breast masses in imaging. More than half (55.88%) of patients in the metachronous group developed primary breast cancer within 5 years after diagnosis of extramammary primary cancer. The median overall survival time was 71 months. Within 90 months, the prognosis of patients with synchronous SPBC was worse than that of patients with metachronous SPBC (p=0.014). Patients with BM had the worst outcome compared with patients with synchronous SPBC and metachronous SPBC (p<0.001).ER/PR-negative status, an interval of less than 6 months between the onset of two tumors, a late stage of first primary malignancy, and an age of diagnosis of first primary malignancy greater than 60 years predicted a worse prognosis for patients with SPBC. The possibility of SPBC should be considered during the follow-up of patients with primary extramammary malignancy, especially within 5 years of the onset of the first tumor. The stage of first primary malignancy and the age at diagnosis of first primary malignancy have an impact on the prognosis of patients with SPBC.

MED 12 gene mutation in a case of bilateral giant juvenile fibroadenoma

Giant juvenile fibroadenoma is a rare variant of more common benign lesion, fibro adenoma observed in younger population. They present with rapidly enlarging single or multiple breast masses in one or both the breast. A 10-year-old pre-pubertal girl presented with large lump in left breast followed by right breast lump. FNAC was suggestive of fibroadenoma, and histopathology confirmed the diagnosis. To understand the genetic basis of common entity like fibroadenoma with a rare presentation in very young age, the tissue block was subjected to gene sequencing and identified MED 12 gene mutation. It leads us to the possibility of new treatment modalities of targeting the causative gene and thus sparing the patient from invasive procedures.

18f-FDG PET/CT helps to find occult carcinoma in a patient with multiple breast masses at magnetic resonance imaging

18f-FDG PET/CT helps to find occult carcinoma in a patient with multiple breast masses at magnetic resonance imaging

Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity

AbstractAbstract 1618 Introduction:Primary breast lymphoma is a rare type of non-Hodgkin lymphoma (NHL), representing about 1% of breast tumors and 2% of extranodal NHL. Diffuse large B-cell lymphoma (DLBCL) is the most common primary subtype presenting in the breast. Due to the low incidence of primary breast DLBCL, outcome data is limited. The aim of this study was to retrospectively assess the natural history of primary breast DLBCL in the pre and post rituximab eras, with specific emphasis on the incidence of local, systemic and central nervous system (CNS) relapses. Methods:Data was retrospectively collected on patients with primary breast DLBCL from seven USA academic medical centers. Institutional review board approval was obtained at each participating site. Patients were identified through institutional databases and tumor registries at each site. Charts were reviewed to obtain demographic and clinical variables including treatment history and dates of relapse and death when applicable. Only patients with stage I/II disease (involvement of breast and localized lymph nodes) were included. All histologies apart from primary DLBCL were excluded. Overall survival (OS) was calculated from the diagnosis date to the date of death or last follow-up. Time to Progression (TTP) was calculated from diagnosis data until the date of pathological evidence of recurrence or death. Data were summarized using descriptive statistics, and survival was analyzed using the Kaplan-Meier method. Results:Between 1984 and 2012, 75 patients were identified who met the eligibility criteria. The median age was 62 years (range 17–87); 81% presented with a palpable mass; 12% had their disease detected incidentally by mammography; 4% presented with B-symptoms; 59% had right breast involvement; 67% had stage I and 33% had stage II disease. The stage-adjusted international prognostic index (IPI) score was 0 in 28% of patients, 1 in 41%, 2, in 25%, 3 in 4% and 4 in 1%. 91% of patients were treated with chemotherapy; 31% of these were treated in the pre-rituximab era and 69% received rituximab. Radiation therapy (RT) was utilized in 68% of patients and was the only treatment modality in 8% of those receiving RT. 8% of patients received CNS prophylaxis with intrathecal chemotherapy. After a median follow-up of 4.5 years (range 0.6 – 20.6 years), the Kaplan-Meier estimated median TTP was 10.4 years (95% CI 6.2 – 14.6 years) and the median OS was 14.6 years (95% CI 6.5 – 22.6 years). The 5-year TTP and 5-year OS were 65% (95% CI 53–77%) and 75% (95% CI 64–86%) respectively. Among the patients who relapsed, 67% occurred within the first 2 years. A total of 7 relapses in the breast were observed, none in patients treated with combination of chemotherapy and RT. In univariate analysis, rituximab exposure was not associated with any difference in TTP or OS. The stage-adjusted IPI was associated with OS; the 5-year OS was 88% (95% CI 79–98%) in patients with a score of 0–1 versus 48% (95% CI 25–71%) in those with a score of 2–4 (log rank p < 0.001). The very limited-disease group with a stage-adjusted IPI of 0 had a 5-year OS of 94% (95% CI 83–100%) compared to all others who had a 5-year OS of 67% (95% CI 52–81%; log rank p = 0.001). There was no difference in TTP and OS in patients with solitary versus multiple breast masses or between patients with tumors less than versus more than 7cm. Patients receiving RT in addition to chemotherapy had a longer TTP than those who did not (log rank p = 0.03), but RT was not associated with an improved OS. Patients who relapsed and underwent stem cell transplant (SCT) had similar OS to those who never relapsed. Ten patients (13%) had CNS relapse (3 with leptomeningeal disease, 5 with brain parenchymal disease and 2 with both). All CNS relapses occurred within the first 2.8 years from the time of diagnosis. There was no difference in the rate of CNS relapse in the patients who received IT prophylaxis versus those who did not. Conclusions:In this multicenter study, the largest published to date, primary breast DLBCL appears to have a worse prognosis than early-stage DLBCL in nodal or other extranodal sites. RT was associated with improved TTP. Patients who relapsed were successfully salvaged with SCT, and had similar survival times to those who never relapsed. A high CNS relapse rate (∼1 in 8 patients, including parenchymal disease in 70%) was observed. The small numbers preclude definitive conclusions on the value of intrathecal prophylaxis or the utility of rituximab. Disclosures:No relevant conflicts of interest to declare.

Rosai–Dorfman disease presenting as multiple breast masses in an otherwise asymptomatic male patient

Rosai–Dorfman disease presenting as multiple breast masses in an otherwise asymptomatic male patient

Metastases to the breast from extramammary malignancies—sonographic features

To evaluate the clinical and sonographic (US) features of metastatic tumors from extramammary malignancies to the breast. This study included 23 patients with pathologically proven metastases in the breast. Two radiologists retrospectively analyzed the images from US (n = 23), mammography (n = 11), and MRI (n = 5) examinations according to BIRADS. Patients presented with a palpable mass or diffuse breast swelling (21/23) or were asymptomatic (2/23). Eighteen patients had solitary or multiple breast masses on US. The common US finding was an ovoid hypoechoic mass with a noncircumscribed margin. The final assessment categories were BIRADS 3 (probably benign finding) in 6 cases (25%) and BIRADS 4 (suspicious abnormality) in 18 cases (75%). In five patients, US displayed a diffuse infiltrative pattern without a focal lesion, which was categorized as BIRADS 4. Metastatic tumors in the breast have a wide range of sonographic appearances, with some resembling benign lesions. Any newly developed mass in a patient with a known history of extramammary malignancy, even with a probably benign US appearance, should undergo biopsy for pathologic confirmation.

Ultrasonographically guided vacuum‐assisted excision for multiple breast masses: Non‐randomized comparison with conventional open excision

This study aimed to evaluate the safety, efficacy, and patient acceptance of ultrasonographically guided vacuum-assisted excision (UGVAE) for multiple breast masses. Ninety-eight patients with low-risk multiple breast masses were non-randomized to either UGVAE or conventional open excision (COE). Clinical data were prospectively collected and analyzed. The two groups were similar with age, side predilection, size and number of lesions. Forty-seven patients had UGVAE with 8-gauge probe and 15 patients with 11-gauge probe. All lesions were removed through same incision. Patients both in UGVAE and COE had complete removal of all imaged evidence of the masses by ultrasonography on initial follow-up. The majority of excised lesions were fibroadenomas and fibrocystic changes. The overall complication rate was 8.1% in UGVAE group and 5.6% in COE group. Patients treated with UGVAE were more highly satisfied with the cosmetic aspects as compared patients with COE. The postprocedure incomplete removal rate was slightly higher in UGVAE than in COE with 12-month follow-up, but the overall difference was not statistically significant. Both seem to be equally safe and effective, but UGVAE has certain advantages, that include minimal residual scar, excellent cosmesis outstanding, offering an useful alternative to the excision of low-risk multiple benign masses.

Acute Lymphoblastic Leukemia Presented as Multiple Breast Masses

Breast metastases in cases leukemia are very rare and occur primarily in patients with acute myeloid leukemia. We report the involvement of breast metastases in a 30-year-old woman with acute T cell lymphoblastic leukemia. The patient's mammograms revealed an extremely dense pattern with ill-defined, denser mass-like lesions in both breasts. A bilateral breast ultrasonographic evaluation revealed lobular-shaped and partly ill-defined hypoechoic masses with a multi-septated nodular (mottled) appearance.

Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy

To review and illustrate the findings in fine needle biopsy (FNB) of extramammary malignancies presenting with breast metastases (MMB). We reviewed 32 cases of MMB diagnosed on breast FNB. The clinical data, with particular attention to the history of a known primary malignancy, previous systemic metastatic disease in other sites and presentation with extramammary disease in addition to a breast mass were examined. The morphological appearances were reviewed and are illustrated, focusing on those features which allow the pathologist to recognise the possibility of metastatic disease and undertake appropriate steps to investigate this. The 32 cases included metastases from a wide range of sites, including cutaneous melanoma (10), lung (8), non-Hodgkin's lymphoma (5), soft tissue (4), colon (2), endometrium, ovary and bladder. There was a history of extramammary malignancy in 26, while in six patients the breast mass was detected at initial presentation with malignant disease. Of the latter six patients, four had evidence of widespread metastases, while one presented with multiple breast masses. In 16 cases the cytological features allowed the possibility of metastases to be recognised without clinical data, while in the other 16 there was sufficient overlap with primary mammary carcinoma that the possibility of metastases could be missed. Only one case was initially mistaken for a primary tumour, in this case the history of prior malignancy with systemic metastases was not provided to the reporting pathologist. The majority (81%) of cases of MMB have a history of primary malignancy, although only a minority have a history of systemic metastases at other sites. Of those patients without known prior malignancy, the majority present with systemic disease or multiple breast lesions. The cytological features allow metastatic disease to be suspected in half of the cases, although in the others, particularly patients with metastatic adenocarcinoma, diagnosis without recourse to immunohistochemistry is difficult or impossible. A combination of complete clinical history, attention to the cytological features and suspicion in cases with metastatic disease beyond the axilla should allow most cases of MMB to be suspected, and suitable material for ancillary confirmatory testing to be obtained.

Excision of 13 phyllodes bilateral breast tumors in one patient

11584 Background: Phyllodes tumors are rare fibroepithelial breast tumors, classified as benign, borderline, or malignant. The prognosis is favorable, with a local recurrence rate of 15% and distant recurrence of 5–10%. Phyllodes tumors require wide excision with negative margins to prevent recurrence. We report a case of multiple bilateral tumors in one patient, an occurrence not yet reported in the world literature. Methods: The medical records of a patient diagnosed with multiple bilateral phyllodes tumors and fibroadenomas of the breast were reviewed. Results: A 16-year old girl reported the presence of palpable bilateral breast masses over the past few years. An initial ultrasound at age 14 revealed “indeterminate” solid masses. Her family history was significant for a grandmother with premenopausal breast cancer. On exam, she had multiple masses palpable bilaterally, with the largest masses of the right breast measuring 8 cm and 5 cm. The largest mass on the left was approximately 9 cm. No lymphadenopathy was present. Ultrasound revealed multiple masses bilaterally, some increased in size, with many suspicious for malignancy, with a BI-RADS score of 4b. Mammography revealed multiple bilateral masses, with many suspicious for cancer. A core biopsy of a left breast mass revealed a possible fibroadenoma, while core biopsy of the right suggested giant juvenile fibroadenoma versus low-grade phyllodes tumor. The patient underwent bilateral excision of multiple breast masses with breast reduction. Final pathology confirmed 15 right breast masses. The dominant mass on the right was a low-grade phyllodes tumor. The other masses consisted of a low-grade phyllodes tumor, 8 benign phyllodes tumors, and 5 fibroadenomas. On the left, 12 breast masses were excised: 3 benign phyllodes tumors, 8 fibroadenomas, and 1 complex fibroadenoma. Conclusions: To our knowledge, we present the first reported case of multiple, bilateral phyllodes breast tumors in an adolescent girl. Multiple bilateral breast masses in a young patient do not always represent benign fibroadenomas or fibrocystic disease. Young patients with multiple bilateral breast masses should receive a thorough evaluation to rule out malignancy. No significant financial relationships to disclose.

Syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex): breast imaging findings.

To study the imaging appearances of breast lesions in female patients with Carney complex. Seven patients with Carney complex underwent mammography (n = 5), ultrasound (US) (n = 6), or magnetic resonance (MR) imaging (n = 6) in a prospective study. Previous breast images in three patients were reviewed. Mammograms in two additional patients were retrospectively reviewed. Thus, nine patients aged 16-61 were included in this study. Mammograms showed well-defined, iso- or hypodense masses; most were not calcified. Two lesions contained calcifications; both were biopsy-proved ductal adenomas. US demonstrated solid, hypoechoic, well-circumscribed masses in six patients and complex cystic masses (myxoid fibroadenomas) in one patient. MR imaging with a fat-suppressed, fast spin-echo, T2-weighted sequence demonstrated high-signal-intensity lesions (n = 5). Fat-suppressed, spoiled gradient-recalled-echo MR images demonstrated hypointense lesions with variable contrast material enhancement (n = 5). Five of seven patients in the prospective review had multiple breast lesions on at least one study. Mammograms and US scans were negative in three patients each. Chest and breast MR images were negative in only one patient. Female patients with Carney complex often have multiple breast masses with variable imaging appearances that probably represent myxoid fibroadenomas or ductal adenomas. MR imaging showed the most lesions. These lesions all demonstrate benign characteristics and should not prompt multiple biopsies.

Apocrine carcinoma: clinical and mammographic features.

To describe the mammographic features of apocrine carcinoma and assess the patterns of calcifications associated with these lesions. Clinical and mammographic features from 17 patients with apocrine carcinoma were retrospectively reviewed. Special attention was paid to the presence of mixed form, diffusely scattered microcalcifications on mammograms. Patients were referred for clinical (n = 10), mammographic (n = 2), or both clinical and mammographic (n = 5) abnormalities. Findings at clinical examination included a palpable breast mass (n = 12), multiple breast masses (n = 1), and bloody nipple discharge (n = 2); two patients had normal findings. Fourteen patients had opacities at mammography. These opacities were associated with microcalcifications in 10 cases. Three patients had microcalcifications without opacities; one of those three patients exhibited a mixed form of diffusely scattered calcifications. Clinical and mammographic features of apocrine carcinoma do not differ from those of invasive ductal carcinoma.

Giant cell arteritis (temporal arteritis) affecting the breast: report of two cases and review of published reports.

The breast is an infrequently recognised site of primary giant cell arteritis. Two cases of giant cell arteritis affecting the breast are described and 11 previously described cases are reviewed. All cases presented with single or multiple breast masses, leading to a diagnosis before biopsy of suspected breast carcinoma. Symptoms similar to those of polymyalgia rheumatica occurred in about half of these patients, though the significance of these symptoms was only appreciated in retrospect. Clinical or pathological evidence of giant cell arteritis outside the breast (temporal artery, thyroid artery) was noted in a minority of cases. Seven patients received corticosteroid treatment, and all patients recovered without complications. Two patients had an adenocarcinoma of the breast contiguous with the giant cell arteritis. Giant cell arteritis affecting the breast may be underrecognised and should be considered in older women with polymyalgia rheumatica-like symptoms and tender breast mass(es).

Mammographic detection of breast cancer.

Mammography, whether film or xerography, is a complementary examination to breast palpation in the detection of breast cancer. According to the guidelines of the American Cancer Society, mammography should be performed on every asymptomatic woman, at least once, over the age of 35. Annual mammography after 50 is also advised. The radiation dose to the breast from current equipment is so low as to not be considered a factor in denying a woman this screening examination. Mammography has a role in evaluating the woman with solitary and multiple breast masses. It is the only proved reliable modality able to detect nonpalpable breast cancers and small tumors less than 2 cm in size. All nonpalpable lesions should be excised by directed biopsy, using a preoperative localization technique.